Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study
Introduction For hemodialysis patients at high risk of bleeding, a regional anticoagulant can be used, such as citrate or nafamostat mesylate (NM). The objective of this study was to evaluate NM as an alternative to citrate for anticoagulation in hemodialysis patients at high risk of bleeding.Method...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2025-12-01
|
| Col·lecció: | Renal Failure |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2464830 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|